Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

British Journal of Haematology

Volumn 172, Issue 1, 2016, Pages 80-88

  Chihara, Dai ^a   Cheah, Chan Y ^a   Westin, Jason R ^a   Fayad, Luis E ^a   Rodriguez, Maria A ^a   Hagemeister, Fredrick B ^a   Pro, Barbara ^b   Mclaughlin, Peter ^a   Younes, Anas ^c   Samaniego, Felipe ^a   Goy, Andre ^d   Cabanillas, Fernando ^e   Kantarjian, Hagop ^a   Kwak, Larry W ^a   Wang, Michael L ^a   Romaguera, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e Haematology   (Puerto Rico)

Author keywords

Hyper CVAD; Mantle cell lymphoma; Methotrexate; Secondary malignancy; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SECOND CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, MANTLE-CELL; MALE; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RITUXIMAB; VINCRISTINE;

EID: 84955656006     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13796     Document Type: Article

References (30)

1. Abrahamsson, A., Albertsson-Lindblad, A., Brown, P.N., Baumgartner-Wennerholm, S., Pedersen, L.M., D'Amore, F., Nilsson-Ehle, H., Jensen, P., Pedersen, M., Geisler, C.H. & Jerkeman, M. (2014) Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study. Blood, 124, 1288-1295.
2. Bernard, M., Gressin, R., Lefrere, F., Drenou, B., Branger, B., Caulet-Maugendre, S., Tass, P., Brousse, N., Valensi, F., Milpied, N., Voilat, L., Sadoun, A., Ghandour, C., Hunault, M., Leloup, R., Mannone, L., Hermine, O. & Lamy, T. (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia, 15, 1785-1791.
3. Bernstein, S.H., Epner, E., Unger, J.M., Leblanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T.P. & Fisher, R.I. (2013) A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology, 24, 1587-1593.
4. Bhatt, V.R., Loberiza, F.R., Armitage, J.O., Greiner, T.C., Bast, M., Lunning, M.A., Bierman, P., Vose, J.M. & Bociek, R.G. (2014) Clinicopathologic features, management and outcomes of blastoid variant (BV) of mantle cell lymphoma (MCL): a nebraska lymphoma study group (NLSG) experience. Blood (ASH Annual Meeting Abstracts), 124, 2971.
5. Chandran, R., Gardiner, S.K., Simon, M. & Spurgeon, S.E. (2012) Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. Leukaemia & Lymphoma, 53, 1488-1493.
6. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
7. Chihara, D., Ito, H., Matsuda, T., Shibata, A., Katsumi, A., Nakamura, S., Tomotaka, S., Morton, L.M., Weisenburger, D.D. & Matsuo, K. (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. British Journal of Haematology, 164, 536-545.
8. Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Ferme, C. & Tilly, H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-2045.
9. Delarue, R., Haioun, C., Ribrag, V., Brice, P., Delmer, A., Tilly, H., Salles, G., Van Hoof, A., Casasnovas, O., Brousse, N., Lefrere, F. & Hermine, O. & Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood, 121, 48-53.
10. Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association, 94, 496-509.
11. Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P., Elonen, E. & Nordic Lymphoma, G. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687-2693.
12. Geisler, C.H., Kolstad, A., Laurell, A., Jerkeman, M., Raty, R., Andersen, N.S., Pedersen, L.B., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P., Elonen, E. & Nordic Lymphoma, G. (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology, 158, 355-362.
13. de Guibert, S., Jaccard, A., Bernard, M., Turlure, P., Bordessoule, D. & Lamy, T. (2006) Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica, 91, 425-426.
14. Hermine, O., Hoster, E., Walewski, J., Ridrag, V., Brousse, N., Thieblemont, C., Bouabdallah, R., Dohner, H., Feugier, P., Forstpointner, R., Haioun, C., Kneba, M., Hanel, M., Casasnovas, O., Mertelsmann, R.H., Hallek, M., Bosly, A., Nowacki, M., Klapper, W., Gisselbrecht, C., Coiffier, B., Unterhalt, M., Hiddemann, W. & Dreyling, M. (2012) Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the european mantle cell lymphoma network (MCL net). Blood (ASH Annual Meeting Abstracts), 120, 623.
15. Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., vanHoof, A., Kluin-Nelemans, H.C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wormann, B., Ludwig, W.D., Duhrsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W. & Unterhalt, M.; German Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma Network. (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111, 558-565.
16. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. & Shipp, M.A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 1288-1294.
17. Jaffe, E., Harris, N., Stein, H. & Vardiman, J. (2001) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Lyon, France.
18. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
19. Khouri, I.F., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., Hagemeister, F., Samuels, B., Rodriguez, A., Giralt, S., Younes, A., Przepiorka, D., Claxton, D., Cabanillas, F. & Champlin, R. (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Journal of Clinical Oncology, 16, 3803-3809.
20. LaCasce, A.S., Vandergrift, J.L., Rodriguez, M.A., Abel, G.A., Crosby, A.L., Czuczman, M.S., Nademanee, A.P., Blayney, D.W., Gordon, L.I., Millenson, M., Vanderplas, A., Lepisto, E.M., Zelenetz, A.D., Niland, J. & Friedberg, J.W. (2012) Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood, 119, 2093-2099.
21. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. & Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984-1992.
22. Merli, F., Luminari, S., Ilariucci, F., Petrini, M., Visco, C., Ambrosetti, A., Stelitano, C., Caracciolo, F., Di Renzo, N., Angrilli, F., Carella, A.M., Capodanno, I., Barbolini, E., Galimberti, S. & Federico, M. (2012) Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. British Journal of Haematology, 156, 346-353.
23. NCCN. (2015) NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphomas (Version 2. 2015), Vol. 2015. National Comprehensive Cancer Network. Fort Washington, PA, USA. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
24. Romaguera, J.E., Fayad, L., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N.H., Wang, M., Beasley, V., Medeiros, L.J., Katz, R.L., Gagneja, H., Samuels, B.I., Smith, T.L. & Cabanillas, F.F. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology, 23, 7013-7023.
25. Romaguera, J.E., Fayad, L.E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M.A., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Cabanillas, F., Kantarjian, H., Kwak, L. & Wang, M. (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. British Journal of Haematology, 150, 200-208.
26. Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., Thiele, J. & Vardiman, J. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Lyon, France.
27. Tarella, C., Passera, R., Magni, M., Benedetti, F., Rossi, A., Gueli, A., Patti, C., Parvis, G., Ciceri, F., Gallamini, A., Cortelazzo, S., Zoli, V., Corradini, P., Carobbio, A., Mule, A., Bosa, M., Barbui, A., Di Nicola, M., Sorio, M., Caracciolo, D., Gianni, A.M. & Rambaldi, A. (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. Journal of Clinical Oncology, 29, 814-824.
28. Tiemann, M., Schrader, C., Klapper, W., Dreyling, M.H., Campo, E., Norton, A., Berger, F., Kluin, P., Ott, G., Pileri, S., Pedrinis, E., Feller, A.C., Merz, H., Janssen, D., Hansmann, M.L., Krieken, H., Moller, P., Stein, H., Unterhalt, M., Hiddemann, W., Parwaresch, R. & European, M.C.L.N. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. British Journal of Haematology, 131, 29-38.
29. Vose, J.M. (2013) Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. American Journal of Hematology, 88, 1082-1088.
30. Williams, M.E. (2013) Transplantation for mantle cell lymphoma: is it the right thing to do? Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2013, 568-574.